Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.

Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, O'Hare T, Deininger MW.

Leukemia. 2018 Apr 18. doi: 10.1038/s41375-018-0131-z. [Epub ahead of print]

PMID:
29749399
2.

Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.

Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, O'Hare T, Deininger MW.

Oncotarget. 2018 Apr 3;9(25):17889-17894. doi: 10.18632/oncotarget.24954. eCollection 2018 Apr 3.

3.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

4.

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.

Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2018 Mar 27. doi: 10.1038/s41375-018-0050-z. [Epub ahead of print] No abstract available.

PMID:
29588547
5.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086. [Epub ahead of print]

PMID:
29567798
6.

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.

Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391.

7.

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.

Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T.

Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. No abstract available.

8.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

9.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

PMID:
28982745
10.

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Tantravahi SK, Guthula RS, O'Hare T, Deininger MW.

Curr Hematol Malig Rep. 2017 Oct;12(5):495-505. doi: 10.1007/s11899-017-0409-7. Review.

PMID:
28852963
11.

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.

Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T.

Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. No abstract available.

PMID:
28819281
12.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

13.

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel AB, O'Hare T, Deininger MW.

Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612. doi: 10.1016/j.hoc.2017.04.007. Review.

PMID:
28673390
14.

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Deininger MWN, Tyner JW, Solary E.

Nat Rev Cancer. 2017 Jun 23;17(7):425-440. doi: 10.1038/nrc.2017.40. Review.

PMID:
28642604
15.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S.

Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.

16.

Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?

Patel AB, Wilds BW, Deininger MW.

Expert Rev Hematol. 2017 Jul;10(7):659-674. doi: 10.1080/17474086.2017.1330144. Epub 2017 May 22. Review.

PMID:
28511567
17.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2017 May;31(5):1253-1254. doi: 10.1038/leu.2017.14. No abstract available.

PMID:
28465516
18.

miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Wallace JA, Kagele DA, Eiring AM, Kim CN, Hu R, Runtsch MC, Alexander M, Huffaker TB, Lee SH, Patel AB, Mosbruger TL, Voth WP, Rao DS, Miles RR, Round JL, Deininger MW, O'Connell RM.

Blood. 2017 Jun 8;129(23):3074-3086. doi: 10.1182/blood-2016-09-740209. Epub 2017 Apr 21.

19.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

20.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

21.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators.

J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.

22.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611.

PMID:
27956542
23.

Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2016 Nov;30(11):2275-2279. doi: 10.1038/leu.2016.218. Epub 2016 Aug 2. No abstract available.

24.

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S.

Haematologica. 2017 Jan;102(1):94-102. doi: 10.3324/haematol.2016.148924. Epub 2016 Sep 15.

25.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.

PMID:
27133948
26.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

27.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
28.

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.

Leukemia. 2016 Jul;30(7):1493-501. doi: 10.1038/leu.2016.51. Epub 2016 Mar 8.

29.

Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.

Ali AM, Gómez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT.

ChemMedChem. 2016 Apr 19;11(8):850-61. doi: 10.1002/cmdc.201600021. Epub 2016 Mar 30.

30.

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Patel AB, Vellore NA, Deininger MW.

Clin Cancer Res. 2016 Mar 1;22(5):1037-47. doi: 10.1158/1078-0432.CCR-15-0905. Review.

31.

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.

Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW.

Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8. No abstract available.

32.

Age-related mutations and chronic myelomonocytic leukemia.

Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.

Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

33.

Molecular monitoring in CML and the prospects for treatment-free remissions.

Deininger MW.

Hematology Am Soc Hematol Educ Program. 2015;2015:257-63. doi: 10.1182/asheducation-2015.1.257. Review.

PMID:
26637731
34.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

35.

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T.

Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19. No abstract available.

36.

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.

37.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.

Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW.

Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196. Epub 2015 Jul 23.

38.

Diagnosing and managing advanced chronic myeloid leukemia.

Deininger MW.

Am Soc Clin Oncol Educ Book. 2015:e381-8. doi: 10.14694/EdBook_AM.2015.35.e381. Review.

39.

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW.

Exp Hematol. 2015 Jul;43(7):537-45.e1-11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24.

40.

A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.

Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS.

Leukemia. 2015 Aug;29(8):1668-75. doi: 10.1038/leu.2015.53. Epub 2015 Feb 27.

41.

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T.

Leukemia. 2015 Sep;29(9):1939-42. doi: 10.1038/leu.2015.42. Epub 2015 Feb 13. No abstract available.

42.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

43.

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.

Blood. 2015 Mar 12;125(11):1772-81. doi: 10.1182/blood-2014-08-588855. Epub 2015 Jan 8.

44.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

45.

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW.

Leuk Suppl. 2014 Dec;3(Suppl 1):S5-6. doi: 10.1038/leusup.2014.3. Epub 2014 Dec 17. No abstract available.

46.

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Eiring AM, Deininger MW.

Genome Biol. 2014 Sep 17;15(9):461. doi: 10.1186/s13059-014-0461-8. Review.

47.

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW.

Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.

48.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Erratum in: Leukemia. 2017 May;31(5):1253-1254.

49.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

50.

Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.

Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI.

J Natl Compr Canc Netw. 2014 Aug;12(8):1113-21.

PMID:
25099443

Supplemental Content

Loading ...
Support Center